Growing community of inventors

Duesseldorf, Germany

Anne Kathrin Volkmer

Average Co-Inventor Count = 8.00

ph-index = 4

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 36

Anne Kathrin VolkmerIrving L Weissman (8 patents)Anne Kathrin VolkmerRavindra Majeti (8 patents)Anne Kathrin VolkmerJie Liu (8 patents)Anne Kathrin VolkmerJens-Peter Volkmer (8 patents)Anne Kathrin VolkmerStephen Willingham (8 patents)Anne Kathrin VolkmerSusan Sweeney Prohaska (8 patents)Anne Kathrin VolkmerMaureen C Howard (6 patents)Anne Kathrin VolkmerAnne Kathrin Volkmer (8 patents)Irving L WeissmanIrving L Weissman (146 patents)Ravindra MajetiRavindra Majeti (45 patents)Jie LiuJie Liu (40 patents)Jens-Peter VolkmerJens-Peter Volkmer (30 patents)Stephen WillinghamStephen Willingham (18 patents)Susan Sweeney ProhaskaSusan Sweeney Prohaska (9 patents)Maureen C HowardMaureen C Howard (11 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Leland Stanford Junior University (8 from 5,307 patents)


8 patents:

1. 12258399 - Methods for achieving therapeutically effective doses of anti-CD47 agents

2. 12258403 - Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody

3. 11603404 - Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

4. 11518806 - Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

5. 11136391 - Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

6. 11104731 - Compositions for achieving therapeutically effective doses of anti-CD47 agents

7. 10301387 - Methods for achieving therapeutically effective doses of anti-CD47 agents

8. 9623079 - Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/10/2025
Loading…